Lateral lymph node study for rectal cancer
Part of Cancer, Digestive system, Heart & circulation clinical trials.
This trial is for people with rectal cancer that is close to the anal opening or has spread to nearby lymph nodes. It aims to understand how to best treat these lateral lymph nodes to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed adenocarcinoma (a type of rectal cancer).
- Your tumor is low in the rectum (within about 3 inches of the anal opening) and is at a certain stage on MRI, OR your tumor is anywhere in the rectum and you have visible lateral lymph nodes (lymph nodes on the sides of the pelvis).
- You have not had your rectal cancer come back before.
- You are not taking part in another trial that might interfere with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial focuses on rectal cancer that has come back in the side lymph nodes near the pelvis. It tests how to treat that “lateral nodal recurrence” to improve outcomes by targeting these specific lymph nodes.
This trial is testing whether a more limited surgery for mid and low rectal cancer can be safe, by avoiding removal of lymph nodes near the main artery. It may be a good fit if your tumor is in the lower rectum, hasn't spread far, and you are in generally good health.
This trial looks at how much the lymph nodes respond to chemoradiation before surgery in people with locally advanced rectal cancer. It aims to understand if that response can predict long-term results and guide future treatment choices.
This trial tests whether removing lymph nodes in the pelvis during laparoscopic surgery for rectal neuroendocrine tumors (a type of slow-growing or aggressive tumor) improves outcomes. It is for people with larger or recurrent tumors, or those at higher risk due to tumor grade or depth.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
Hear when a new Rectal Neoplasm Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.